JP2022546985A5 - - Google Patents

Info

Publication number
JP2022546985A5
JP2022546985A5 JP2022513552A JP2022513552A JP2022546985A5 JP 2022546985 A5 JP2022546985 A5 JP 2022546985A5 JP 2022513552 A JP2022513552 A JP 2022513552A JP 2022513552 A JP2022513552 A JP 2022513552A JP 2022546985 A5 JP2022546985 A5 JP 2022546985A5
Authority
JP
Japan
Prior art keywords
administering
subject
therapeutically effective
effective dose
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048932 external-priority patent/WO2021046048A1/en
Publication of JP2022546985A publication Critical patent/JP2022546985A/ja
Publication of JP2022546985A5 publication Critical patent/JP2022546985A5/ja
Priority to JP2024192261A priority Critical patent/JP2025028853A/ja
Pending legal-status Critical Current

Links

JP2022513552A 2019-09-02 2020-09-01 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物 Pending JP2022546985A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192261A JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894929P 2019-09-02 2019-09-02
US62/894,929 2019-09-02
US201962913667P 2019-10-10 2019-10-10
US62/913,667 2019-10-10
PCT/US2020/048932 WO2021046048A1 (en) 2019-09-02 2020-09-01 Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192261A Division JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Publications (2)

Publication Number Publication Date
JP2022546985A JP2022546985A (ja) 2022-11-10
JP2022546985A5 true JP2022546985A5 (enExample) 2023-09-08

Family

ID=74853433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513552A Pending JP2022546985A (ja) 2019-09-02 2020-09-01 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物
JP2024192261A Pending JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192261A Pending JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Country Status (9)

Country Link
US (1) US12691151B2 (enExample)
EP (1) EP4025230B1 (enExample)
JP (2) JP2022546985A (enExample)
KR (1) KR20220054865A (enExample)
CN (1) CN114667154A (enExample)
AU (1) AU2020340934A1 (enExample)
CA (1) CA3152787A1 (enExample)
IL (1) IL290974A (enExample)
WO (1) WO2021046048A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
CN116077505B (zh) * 2023-01-17 2024-09-06 广东省人民医院 Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431349A1 (en) 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
WO2004015118A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Similar Documents

Publication Publication Date Title
MX2020012270A (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t.
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
JP2022505022A5 (enExample)
JP2023508357A5 (enExample)
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
AR059482A1 (es) Uso de supresion inmune local para potenciar terapia viral oncolitica
JP2017524735A5 (enExample)
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021003033A (es) Formulaciones de compuestos de cicloserina y aplicaciones de estas.
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
EP3858369A4 (en) CANCER THERAPY USING ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR IN COMBINATION, AND PHARMACEUTICAL COMPOSITION AND COMBINATION DRUG USED THEREIN
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CO2019014496A2 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes
PE20221768A1 (es) Inhibidores de egfr
MX2021011871A (es) Uso de virus oncoliticos en la terapia neoadyuvante del cancer.
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CL2020003171A1 (es) Dosis y efecto de un antagonista de c5a con una vasculitis asociada a anca.
AR056487A1 (es) UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA
BR112019023064A2 (pt) tratamento de carcinoma hepatocelular
EA201101036A1 (ru) Применение хлорида аммония в терапии
MX2021014523A (es) Metodos para tratar colangiocarcinoma.